Efficacy of Intermediate and High Intensity Regimens in Patients With Relapsed Acute Lymphoblastic Leukemia. Experience of Two Centers in Mexico City
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 56
- Locations
- 2
- Primary Endpoint
- Overall survival
Study Overview
Brief Summary
The aim of this study is to describe the survival and relapses of patients with diagnosis of acute lymphoblastic leukemia at two tertiary level hospitals in the metropolitan area of the valley of Mexico
Detailed Description
Retrospective, observational study in patients with diagnosis of acute lymphoblastic leukemia, according to the criteria of the World Health Organization, from July, 2016, to October, 2020. The patients were cared for in the hematology department of the Hospital General de Mexico and in the hematology department of the Hospital Regional de Alta Especialidad Ixtapaluca. Relapse was considered in those cases with more than 5% of blasts in bone marrow and as relapse to the central nervous system with the presence of blasts in cerebrospinal fluid.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 15 Years to 60 Years (Child, Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with diagnosis of acute lymphoblastic leukemia according to the criteria of the World Health Organization.
Exclusion Criteria
- •Age less than 15 years
- •Age over 60 years
Outcomes
Primary Outcomes
Overall survival
Time Frame: 4-years
Progression free survival
Time Frame: 4-years
Number of relapses
Time Frame: 4-years
Cases with more than 5 percent of blasts in bone marrow and as relapse to the central nervous system with the presence of blasts in cerebrospinal fluid
Secondary Outcomes
No secondary outcomes reported
Investigators
Christian Omar Ramos-Peñafiel, MD, PhD
Head of the hematology hospitalization area
Hospital General de Mexico